Characteristics and disease-related features and treatment profiles of the cases and their matched controls (204 pairs) at the onset of liver abnormalities.
| Variables | Cases, n = 204 | Controls, n = 204 | p |
|---|---|---|---|
| Whites, n (%) | 168 (82) | 168 (82) | 1.00 |
| Duration of psoriasis, yrs, mean (SD) | 25.1 (14.7) | 21.3 (13.8) | 0.009 |
| Duration of PsA, yrs, mean (SD) | 16.5 (11.2) | 10.4 (10.3) | < 0.001 |
| Daily alcohol intake, n (%) | 19 (10) | 12 (6) | 0.14 |
| Employment, n (%) | 89 (44) | 135 (66) | < 0.001 |
| PASI score, mean (SD) | 4.0 (7.3) | 3.5 (5.3) | 0.40 |
| Active (swollen or tender) joint count, mean (SD) | 4.8 (8.6) | 3.4 (6.1) | 0.06 |
| Clinically damaged joint count, mean (SD) | 8.3 (13.1) | 3.4 (7.8) | < 0.001 |
| ESR, mm/h, mean (SD) | 16.9 (17.4) | 13.8 (12.4) | 0.04 |
| Elevated CRP, n (%) | 77 (38) | 67 (33) | 0.30 |
| Positive RF, n (%) | 6 (3) | 3 (2) | 0.36 |
| Positive ANA, n (%) | 31 (15) | 27 (13) | 0.57 |
| Hypertension, n (%) | 115 (56) | 66 (32) | < 0.001 |
| Hyperlipidemia, n (%) | 51 (26) | 25 (12) | < 0.001 |
| Diabetes, n (%) | 25 (13) | 16 (8) | 0.12 |
| BMI, kg/m2, mean (SD) | 30.1 (6.5) | 28.7 (5.6) | 0.03 |
| Use of NSAID, n (%) | 41 (20) | 59 (29) | 0.04 |
| Use of nonbiological DMARD, n (%) | 83 (41) | 71 (35) | 0.22 |
| Use of TNFi, n (%) | 92 (45) | 70 (37) | 0.03 |
PsA: psoriatic arthritis; PASI: Psoriasis Area and Severity Index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor; ANA: antinuclear antibodies; BMI: body mass index; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs; TNFi: tumor necrosis factor inhibitors.